PanTera secures two key permits for Actinium-225 Production Facility in MolTwo key permits required to initiate construction of its state-of-the-art Actinium-225 (Ac-225) Production Center (APC) in Mol, Belgium have been granted to PanTera. The environmental permit was granted by the Province of Antwerp, and the nuclear permit by the Federal Agency for Nuclear Control (FANC/AFCN), the two permits mark a critical step forward in PanTera’s mission to secure a global supply of Ac-225 for targeted alpha therapy in cancer treatment.Read more PanTera produces and supplies first Actinium-225 extracted from Thorium-229 in BelgiumIn June 2025, PanTera has successfully extracted and supplied Actinium-225 (Ac-225) from its Thorium-229 (Th-229) generator, installed at its production facility in Belgium. This achievement marks the first delivery of Ac-225 under PanTera’s "Early Supply" program, powered by Th-229 material provided by TerraPower Isotopes.Read more PanTera signs an agreement with SK Biopharmaceuticals for the supply of actinium-225On February 25, 2025, SK Biopharmaceuticals announced their collaboration with PanTera marking a significant step forward in the global interest surrounding Actinium-225.
This partnership leverages PanTera's expertise in delivering high-purity Actinium-225, a crucial resource for innovative therapeutic applications for cancer treatments.26/02/2025Read more A new Partnership with Cody ASThis partnership is a significant milestone for our radiochemistry process. Cody’s expertise in engineering complex radiochemical systems gives us confidence that they will deliver innovative and reliable solutions to meet the growing global demand for Ac-225!Read more PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 productionPanTera today announces that it has completed a EUR 93 million oversubscribed Series A fundraise led by EQT Life Sciences, with additional equity and debt funding bringing the total amount raised to EUR 134 million.
Sven Van den Berghe, CEO of PanTera, said: “With this funding, we are now en route to realise our vision of providing a “Better Fight for Life” to cancer patients worldwide by becoming a dependable global 225Ac supplier.”
Read More to see our full Press Release.Read more Tractebel and Modulo architects strengthen their partnership with PanTera to design a medical radioisotope production facilityJointly with its partner Modulo architects, Tractebel will combine its infrastructure and nuclear expertise to support the design and construction of PanTera's actinium-225 production facility in Belgium, enabling breakthrough cancer treatment production Read more PanTera signs a second agreement for the supply of actinium-225PanTera’s continues to deploy its strategy to become a market leader into the production and distribution of Ac22514/03/2024Read more PanTera signs agreement with Bayer for the supply of actinium-225Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients.13/02/2024Read more 
